PF-Atlas › Clinical Trials › NCT04040361

Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer

Pembrolizumab · Phase 2

Registry ID

NCT04040361

Phase

Phase 2

Status

Unknown

Drug / intervention

Pembrolizumab

Sponsor

Masahiro Tsuboi

Start

2019-11-30

Enrollment

Locations

About this trial

The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab

View NCT04040361 on ClinicalTrials.gov →

Explore related

All Pembrolizumab trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT04040361 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.